|
Combinatorial drug therapies |
Compounds | Mechanism | Cancer type | Role of autophagy | References |
|
5-Flurouracil and si-Beclin-1 | Inhibit nucleic acid synthesis | Esophageal cancer Liver cancer | Prodeath Prodeath | [29] [39] |
CQ, Oxaliplatin and Bevacizumab | Inhibition of autophagy by CQ sensitizes cells to Oxaliplatin and Bevacizumab treatment | Colorectal cancer | Prodeath | [83] |
Compound C and Bafilomycin | Inhibit AMPK activity | Brain cancer | Prodeath | [84] |
CQ and ADZ5363 | Inhibit Akt signaling pathway downstream and reduce phosphorylated-mTOR and p-RPS6KB/p70S6K | Prostate cancer | Prodeath | [85] |
CQ and NVP-BEZ235 CQ and XL765 | Inhibition of autophagy by CQ sensitizes cells to dual PI3K/mTOR treatment | Brain cancer | Prodeath Prodeath | [81] [82] |
Gemcitabine and Cannabinoid | Increase ceramide | Pancreatic cancer | Prodeath | [86] |
Lucanthone and Vorinostat | Enhance activity of histone deacetylase inhibitor, Vorinostat | Breast cancer | Prodeath | [68] |
Obatoclax and Lapatinib | Increase expression of NOXA, leading to displacement of Mcl-1 from Beclin-1 | Breast cancer | Prodeath | [87] |
Pyrvinium pamoate and 2-DG | Pyrvinium pamoate inhibits 2-DG-triggered accumulation of LC3 puncta | Cervical cancer Colorectal cancer | Prodeath Prodeath | [88] |
Sorafenib and Pemetrexed | Increase levels of Akt, p70 S6K, and/or phosphorylated-mTOR | Brain, breast, liver, and lung cancers | Prodeath | [48] |
Tamoxifen and deacetylase | Prevent HMGB1: Beclin-1-mediated autophagy from promoting drug resistance | Osteosarcoma | Prodeath | [89] |
Valproic acid and Tubacin | Inhibit HDAC6 specifically | Ovarian cancer | Prodeath | [90] |
|